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Abstract: Matrix metalloproteinases (MMPs) are a family of more than twenty five 
secreted and membrane-bound zinc-endopeptidases which can degrade extracellular matrix 
(ECM) components. They also play important roles in a variety of biological and 
pathological processes. Matrix metalloproteinase inhibitors (MMPIs) have been identified 
as potential therapeutic candidates for metastasis, arthritis, chronic inflammation and 
wrinkle formation. Up to present, more than 20,000 new compounds have been isolated 
from marine organisms, where considerable numbers of these naturally occurring 
derivatives are developed as potential candidates for pharmaceutical application. 
Eventhough the quantity of marine derived MMPIs is less when compare with the MMPIs 
derived from terrestrial materials, huge potential for bioactivity of these marine derived 
MMPIs has lead to large number of researches. Saccharoids, flavonoids and polyphones, 
fatty acids are the most important groups of MMPIs derived from marine natural products. 
In this review we focus on the progress of MMPIs from marine natural products. 
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Abbreviations: MMPs, matrix metalloproteinases; ECM, extracellular matrix; MMPIs, 
matrix metalloproteinase inhibitors; TIMPs, tissue inhibitors of metalloproteinase; RECK, 
reversion-inducing cysteine-rich protein with kazal motifs; ADAMs, a disintegrin and 
metalloproteinases; SAR, safety analysis report; COS, chitooligosaccharides; HDFs, 
human dermal fibroblasts ; CCOS, carboxylated chitooligosaccharides; SGlc, sulfated 
glucosamine; NF-κB, nuclear factor κB; AP-1, activator protein-1; λ-CO, λ-carrageenan 
oligosaccharides; HUVECs, human umbilical vein endothelial cells ; SIP-SII, sulfated S. 
maindroni ink polysaccharide ; EC, Ecklonia cava  
__________________________________________________________________________________ 
 
1. Introduction   
 
Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases that degrade 
extracellular matrix (ECM) components and play important roles in a variety of biological and 
pathological processes
 [1]. MMPs regulate the synthesis and secretion of cytokines, growth factors, 
hormone receptors，and cell adhesion molecules. They also contribute to the growth and development, 
morphogenesis, tissue remodeling, angiogenesis, arthritis, cardiovascular disease, stroke, multiple 
sclerosis, neurodegenerative diseases, allergies, as well as cancer and a series of physiological and 
pathological processes
  [2, 3]. In tumor progression MMPs are important not only in invasion, 
angiogenesis, and metastasis, but also MMPs have roles in cancer cells transformation, growth, 
apoptosis, signal transduction and immune regulation
 [4, 5]. Therefore, the development of matrix 
metalloproteinase inhibitors (MMPIs) to treat some important diseases, including cancers, 
neurodegenerative diseases, cardiovascular diseases and various kinds of inflammatory diseases have 
broad prospects [3-9]. 
Generally MMPs consist of a propeptide domain having about 80 amino acids, a catalytic 
metalloproteinase domain of about 170 amino acids, a linker peptide of variable lengths (also called 
the “hinge region”) and a hemopexin domain of about 200 amino acids [10]. However, not all of these 
domains are essential for MMPs; some MMPs lack the linker peptide and the hemopexin domain. 
MMPs contain a Zn
2+ catalytic core; this zinc-binding site has a conservative HEXXHXXGXXH 
amino acid sequence. The catalytic domains of MMPs show homology, as their three-dimensional (3D) 
structure of the enzyme active site are highly conservative. The catalytic domain includes a pocket 
called the“S1' pocket” located to the right of the zinc atom. This pocket is hydrophobic in nature, but 
variable in depth depending on the MMP. It is therefore one of the determining factors of substrate 
specificity of MMPs. Accordingly, the S1' pocket in the catalytic domains of MMPs is most notable, 
and its depth, as well as the length and amino acid sequence of the peptide which around the S1' pocket 
is important basis for design and synthesis of the MMPIs [11-13]. 
MMPs’ activities can be regulated by endogenous inhibitors, such as tissue inhibitors of 
metalloproteinase (TIMPs), α2-macroglobin, heparin and the reversion-inducing cysteine-rich protein 
with kazal motifs (RECK) [4, 5]. There are four TIMPs in humans (TIMP-1, -2, -3 and -4) with 22–29 
kDa. TIMP-1 and TIMP-3 are glycoproteins, but TIMP-2 and TIMP-4 do not contain carbohydrates. 
They inhibit all MMPs tested so far
 [14]. These four TIMPs have different expression and distribution 
in the tissue and may be responsible for regulating the activity of a large number of protease families Mar. Drugs 2009, 7                   
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in vivo, including the metalloproteinases of a disintegrin and metalloproteinases (ADAMs) family. 
However, the TIMPs and other endogenous inhibitors have diversity of biological functions and also 
the protein delivery techniques are not developed, the use of these endogenous inhibitors in clinical 
applications have been delayed [4, 5].   
Design and synthesis of MMPIs has gone through several stages of development over the past 20 
years
 [13]. Originally MMPIs was designed by simulating MMPs substrate, this is the first-generation 
of MMPIs. Most of them are peptides and their derivatives. Inhibition is occurred by chelating the Zn
2+ 
of the MMP by the group present in inhibitors, such as hydroxylamine, carboxyl, SH, etc.. Mainly the 
Zn
2+ is chelated with the oxyammonia-base by combining the substrate analogs peptide, at the same 
time through the substrate analogs peptide combine with the catalytic domains of MMP, and thus plays 
the inhibitory effect. Strong Zn
2+ chelating agents such as hydroxamate as a class of MMPIs have been 
developed, representative of these inhibitors are the British Biotech's Batimastat (BB-94) and 
Marimastat (BB-2516), and they all have ideal inhibitory activity with the MMPs. Even through, these 
compounds can interact with Zn
2+; they can’t distinguish between different MMPs. Therefore, the uses 
of first-generation of MMPIs as drugs in clinical applications were restricted. Their shortcomings 
include: poor selectivity of MMPs, hydroxylamine substances have low oral bioavailability, the 
metabolism is not stable, poor solubility and the drug toxicity increase after amelioration. Therefore it 
was strongly suggested that the first generation of MMPIs must use another group in place of 
hydroxylamine group as a Zn
2+ chelating group, or design new non-peptide MMPIs. For these 
proposed MMPIs, first, lead compounds were selected through high-throughput screening, then these 
lead compounds are reformed with the Safety Analysis Report (SAR) guidance, finally these new 
reagents with better effect was formed. The second-generation MMPIs also contain Zn
2+ chelating 
group. These drugs have eliminated some of shortcomings of peptide drugs with considerable 
selectivity towards MMPs. However, in clinical applications they also have been impeded due to 
effectiveness and side effects [15, 16]. 
Clinical trials for the anti-cancer and anti-arthritis effects have been carried out using many early 
MMPIs. However, only a few MMPIs were effective (such as Marimastat, the overall survival rate of 
the gastric cancer and pancreatic cancer patients increase). Therefore they have not been used in the 
later stages of clinical trials. At present, only one MMPI (Periostat) is being used clinically for 
periodontitis therapy [5, 15]. 
With intensive studies on MMPs, the MMPs host-cell defense functions and physiological functions 
have been discovered by researchers. The early MMPIs whether peptide inhibitors or small molecule 
inhibitors, their activities are most dependent on the Zn
2+ chelating group and MMPs S1' pocket 
combined group. However the Zn
2+ chelating group also reduces these early MMPIs’ selectivity. In 
addition, these early MMPIs inhibit some MMPs physiological functions and some other 
metalloprotease such as DPP III and leucine aminopeptidase, when they inhibit the abnormal MMPs in 
pathology situation [5, 17].   
To sum up the above arguments, the clinical trials of MMPIs in broad-spectrum, face the obstacle, 
as well as the normal physiological functions of MMPs should be further studied for the choice of 
drugs which are selectively acting on them for the MMPs relevant diseases. MMPs S1' pocket 
determine the specificity of substrates and inhibitors in a large extent, therefore the S1' pocket is very 
important for the design and synthesis of MMPIs. Design of MMPIs should be based on the unique Mar. Drugs 2009, 7                   
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functions of MMPs S1' pocket, not only to increase the selectivity for this MMP, but also greatly 
reduce the inhibition of other class of metalloprotease such as ADAMs. At present, development of the 
new generation of MMPIs is guided by this idea. In addition, development of new type of MMPIs with 
different inhibiting mechanisms can increase the drugs' selectivity; which may play a key role in the 
treatment of various diseases related to MMPs [18-21]. 
Broadly speaking, the mechanisms of inhibiting the activity of MMPs include, direct inhibition of 
the enzymes, blocking the MMPs proenzyme activation, suppressing the synthesis of MMPs in the 
gene level, and so on. The MMPIs can be divided into four classes: the natural MMPIs secreted by 
tissues; synthetic MMPIs; MMPIs screened from natural products and the MMPIs screened from the 
phage display random peptide library and antibody library. The synthetic MMPIs and natural product 
derived MMPIs are the hot spots. In recent years, due to the synthetic small molecule inhibitors meet a 
variety of issues in clinical applications, more attention is given to the research of MMPIs derived 
from natural products.   
Lots of successful research work have been conducted to identify MMPIs from land natural 
products, also got a lot of results. For instance, Kim et al. were screened for nearly 90 kinds of extracts 
from clinical application herbal medicines, and found that the extracts from Baicalin, Cinnamon, 
Euonymus, and Magnolia have strong inhibitory effects on MMPs [22-24]. However we should not 
forget that the ocean is treasure house which is full of natural products with amazing biological and 
pharmacological activities. About 80% of the planet's animal and plant growth in the ocean, and the 
variety of marine bacteria can reach 500-100 million. Therefore discovering the ideal MMPIs from 
marine natural products is a very hot topic at present. The leitmotiv along this review is to sum up the 
progress of research work carried out on identifying MMPIs from marine natural products. We divided 
the marine derived MMPIs into three classes, marine saccharoid MMPIs, marine flavonoids and 
polyphenols MMPIs and marine fatty acid MMPIs, and their properties will be discussed in this 
review. 
 
2. MMPIs from marine natural products 
 
2.1. Marine saccharoid MMPIs 
 
The marine saccharoid MMPIs are very popular among marine derived MMPIs area. The most of 
marine saccharoid MMPIs inhibit MMP by direct down-regulation of MMP-9 transcription or via 
inhibition of activator protein-1(AP-1) pathway or nuclear factor κB (NF-κB) pathway. Kim et al. 
report the inhibitory effect of chitooligosaccharides (COS) on activation and expression of matrix 
metalloproteinase-2 (MMP-2) in primary human dermal fibroblasts (HDFs) for the first time. COS 
with 3–5 kDa exhibited the highest inhibitory effect on MMP-2 activity in HDFs, and protein 
expression of MMP-2 was also inhibited by COS with same molecular weight. This inhibition was 
caused by the decrease in gene expression and transcriptional activity of MMP-2[25]. Quang et al. 
have investigated the effect of Chitooligosaccharides (COS) on activity and expression of MMP-9 in 
HT1080 cells by gelatin zymography, RT-PCR, gene reporter assay, and western blot analysis. They 
found that MMP-9 inhibition in the presence of COS was clearly observed in gelatin zymography. 
Specifically, 1- to 3-kDa COS (COS-I) exhibited the highest inhibitory effect on MMP-9 activity in Mar. Drugs 2009, 7                   
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HT1080 cells among tested molecular mass fractions. It was also found that COS-I was capable of 
inhibiting both gene and protein expression of MMP-9 (P<0.01) [26]. The novel low molecular-weight 
carboxylated Chitooligosaccharides (CCOS) has been evaluated for MMP-9 inhibitory effect on 
human fibrosarcoma cell line [27]. A clear dose-dependent inhibition on MMP-9 mediated 
gelatinolytic activities were observed in HT1080 cells following the treatment with CCOS in 
zymography experiments. Transfection studies carried out with MMP-9 and AP-1 reporter constructs 
suggested that the observed reduction in MMP-9 expression was due to down-regulation of MMP-9 
transcription which mediated via inhibition of AP-1. However, in the presence of CCOS, NF-κB and 
TIMP-1 expression levels remained constant [27].   
Adriana et al. investigated on the shrimp heparin-like glycosaminoglycan isolated from L. vannamei 
which was able to interfere on MMP-9 activity in activated human leukocytes. And it has the capacity 
to reduce 90% MMP-9 activity, either in a lower or higher concentrations (10 and 100 μg/mL), with 
pronounced effects [28].In present studies, sulfated glucosamine (SG) has been reported to relieve joint 
pain and inflammation in many arthritis patients. Niranjan et al. studied for SG inhibitory effects on 
MMP-2 and MMP-9 in human fibrosarcoma cells. Expression and activity of above MMPs studied 
suggested SG as a potent MMP inhibitor, and inhibition of MMP-2 and MMP-9 was due to 
down-regulation of transcription factor, NF-κB. However, expression of activator protein-1 (AP-1) was 
not affected by SG treatment. Moreover, down-regulation of NF-κB resulted in production of low 
levels of both NF-κB p50 and p65 proteins and directly affected activation process of MMP-2 and 
MMP-9 expressions [29]. 
Angiogenesis is involved in initiating and promoting several diseases such as cancer and 
cardiovascular events. Chen et al. obtained highly sulfated λ-carrageenan oligosaccharides (λ-CO) by 
carrageenan depolymerization. They have demonstrated that λ-carrageenan oligosaccharides could 
effectively inhibit angiogenesis in the CAM (chick chorioallantoic membrane) model and human 
umbilical vein endothelial cells (HUVECs). Significant inhibition of vessel growth was observed at 
200 μg/pellet. A histochemistry assay also revealed a decrease of capillary plexus and connective tissue 
in λ-CO treated samples. λ-CO inhibited the viability of cells at the high concentration of 1 mg/mL, 
whereas it affected the cell survival slightly (>95%) at a low concentration (<250 μg/mL). Furthermore, 
the inhibitory action of λ-CO was also observed in the endothelial cell invasion and migration at 
relatively low concentrations (150−300  μg/mL), through down-regulation of intracellular matrix 
metalloproteinases (MMP-2) expression on endothelial cells. [30]. 
Wang et al. isolated the sulfated S. maindroni ink polysaccharide (SIP-SII) from cuttlefish Sepiella 
maindroni， and examined the effects of SIP-SII on the expression of matrix metalloproteinases MMP-2 
and MMP-9 as well as tumor cell invasion and migration. SIP-SII (0.8-500 mg/ml) significantly 
decreased the expression of MMP-2 activity in human ovarian carcinoma cells SKOV3. No significant 
decrease of MMP-9 was detected in the cell line after SIP-SII treatment [31]. 
Fucoidan is a uniquely-structured sulfated polysaccharide found in the cell walls of several types of 
brown seaweed which has been recently evaluated for its bioactivities by Ye et al. [32]. 
Enzyme-digested fucoidan extracts prepared from seaweed, Mozuku of Cladosiphon novae-caledoniae 
kylin showed in vitro invasion and angiogenesis abilities of human tumor cells. The mechanism of 
significant inhibition of HT1080 cells invasion by fucoidan extracts, possibly via suppressing MMP-2 
and MMP-9 activities. Further, they investigated the effects of the fucoidan extracts on angiogenesis of Mar. Drugs 2009, 7                   
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human uterine carcinoma HeLa cells, and found that fucoidan extracts suppressed expression and 
secretion of vascular endothelial growth factor (VEGF) [32].   
Marine saccharoid MMPIs exhibit high MMPs inhibitory activity either by direct inhibition of the 
enzyme or by inhibiting the expression of MMPs. And also these marine saccharoid MMPIs have 
shown low toxicity levels. However, due to high molecular weight of theses MMPIs the 
structure-activity relationship and also the mechanism of the activities are hard to be addressed by the 
researchers. If these shortcomings are overcome in the future, marine saccharoid MMPIs have a great 
potential to be used in clinical applications. 
 
2.2. Marine flavonoids and polyphenols MMPIs 
 
Flavonoid glycosides, isorhamnetin 3-O-b-D-glucosides, and quercetin 3-O-b-D-glucoside were 
isolated from Salicornia herbacea and their inhibitory effects on matrix metalloproteinase-9 and -2 
were evaluated in human fibrosarcoma cell line [31]. These flavonoid glycosides led to the reduction 
of the expression levels and activities of MMP-9 and -2 without any significant difference between 
these flavonoid glycosides in zymography experiments. Protein expression levels of both MMP-9 and 
MMP-2 were inhibited and TIMP-1 protein level was enhanced by these flavonoid glycosides [33]. 
Kim et al., for the first time, report a detailed study on the inhibitory effects of phlorotannins in 
brown algae, Ecklonia cava (EC) on MMP activities. A novel gelatin digestion assay could visualize 
complete inhibition of bacterial collagenase-1 activity at 20 μg/ml of EC extract during preliminary 
screening studies. Sensitive fluorometric assay revealed that EC extract can specifically inhibit both 
MMP-2 and MMP-9 activities significantly (P<0.001) at 10 μg/ml. In addition, artificially induced 
activities of MMP-2 and MMP-9 in human dermal fibroblasts and HT1080 cells were inhibited by EC 
extract in a more or less similar manner to the positive control doxycycline. More interestingly, EC 
extract did not exert any cytotoxic effect even at 100 μg/ml, anticipating, its potential use as a safe 
MMP inhibitor [34]. 
The active compound from methanol extracts prepared from roots of Rhodiola sacra has been 
identified as 3-(3, 4-dihydroxy-phenyl)-acrylic acid phenethyl ester (caffeic acid phenethyl ester, 
CAPE) [35, 36]. And Lee et al. found that these active compounds can down-regulate enhanced MMP 
-9 activities [37]. 
Joe et al. examined the inhibitory effects of 29 seaweed extracts on transcriptional activities of 
MMP-1 expression. And found that the eckol and dieckol from Ecklonia species have showed strong 
inhibition of both NF-κB and AP-1 reporter activity, which were well correlated with their abilities to 
inhibit MMP-1 expression. In addition, MMP-1 expression was dramatically attenuated by treatment 
with the eckol or dieckol [38]. 
Matrix metalloproteinases (MMPs), a key component in photoaging of the skin due to exposure to 
ultraviolet A, appear to be increased by UV-irradiation-associated generation of reactive oxygen 
species (ROS). Ryu et al. demonstrates that the alga Corallina pilulifera methanol extract which has 
been shown a high phenolic content, reduced the expression of UV-induced MMP-2 and -9 in human 
dermal fibroblast by dose dependently manner, and has also antioxidant activity capable of strongly 
inhibiting free radicals [39]. 
In murine asthma model, Kim et al. observed that MMP-9 expression was significant reduced via Mar. Drugs 2009, 7                   
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the administration of Ecklonia cava extracts. And Ecklonia cava extracts reveal Suppressor of cytokine 
signaling-3 (SOCS-3) expression and a reduction in the increased eosinophil peroxidase (EPO) 
activities. Their results indicate that Ecklonia cava extracts may prove to be a useful therapeutic agent 
for the treatment of ovalbumin -induced asthma [40]. 
The compounds eckol, 2dieckol, 6,6’-bieckol and 1-(3’,5’-dihydroxyphenoxy) 
-7-(2”,4”,6”-trihydroxy-phenoxy)-2,4,9-trihydroxydibenzo-1,4,-dioxin were extracted from brown 
algae, Ecklonia cava, and Ryu et al. have investigated these compounds inhibited the proinflammatory 
cytokines induced expression of MMP-1, -3 and -13 [41]. 
Flavonoids and polyphenols MMPIs have excellent MMPs inhibitory activities; however they show 
a high toxicity level. Therefore, the pharmaceutical applications of these MMPIs are limited. 
Researchers should pay attention to reduce their toxicity levels by altering the structure in a way by 
preserves it`s bioactivity. Then this class of MMPIs will gain a huge potential to be used in clinical 
applications  
 
2.3. Marine fatty acid MMPIs 
 
Researchers have identified that the long-chain fatty acids could inhibit MMPs. however for 
different MMPs the degree of inhibition is different, such as oleic acid, elaidic acid can inhibit MMP-2 
and MMP-9 with the micromol Ki values, although their inhibitory effects on collagenase-1 (MMP-1) 
are weak, as assessed using synthetic or natural substrates [42]. The fatty acid chain length and its 
degree of saturation is related to the level of inhibition, as the fatty acids with long carbon chains 
showed stronger inhibition than the short ones, and the nonsaturation degree showed a positive 
correlation to the overall inhibitory capacity of the fatty acid chains [42,43]. Fatty acids also bind to 
neutrophil elastase, the parinaric acids, fluorescent-conjugated tetraenoic fatty acids of plant origin, are 
inhibitors of neutrophil elastase. cis-Parinaric acid (cis-PA) interacts with the enzyme in two inhibitory 
modes. The high affinity interaction (Ki = 55 +/- 6 nM) results in partial noncompetitive inhibition of 
amidolytic activity, with 82% residual activity. A lower affinity interaction with cis-PA (Ki = 4 +/- 1 
microM) results in competitive inhibition [44, 45]. the fatty acids also bind to plasmin, such as The 
ability of oleic acid to modulate fibrinolysis was measured by following the urokinase-mediated and 
plasminogen-dependent cleavage of 125I-labelled fibrin clots. Oleic acid levels within the 
physiological range exerted a concentration-dependent inhibition of urokinase-mediated fibrinolytic 
activity [46, 47], and some other serine proteinases, meanwhile modulate their catalytic activities. 
It is well known that the marine fishes are rich in omega-3 long-chain polyunsaturated fatty acids 
(ω3 LC-PUFAs), especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are 
active nutrients [48]. Suzuki et al. found that the inhibition of lung metastasis of a colon cancer cell 
line by EPA and DHA was associated with a reduced activity of MMP-9， however MMP-2 activity was 
not affected by the diet containing PUFAs [49, 50]. The MMP-9 activity was reduced by in uterus, 
placenta and liver tissues of rat fed diets enriched with DHA, with a decreased activity of MMP-2 [50]. 
They explained their finding by a competition of the ω3 LC-PUFAs with arachidonic acid for 
incorporation into membrane phospholipids. This would consequently change the production of 
prostaglandin PGE2 and thereby affect on MMP activities. 
Acetylenic fatty acids isolated from marine sponges have exhibited wide range of biological Mar. Drugs 2009, 7                   
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activities such as cytotoxicity [51], antimicrobial [52] and antifouling [53] activities, and enzyme 
inhibition [54]. Callysponginol sulfate A is the first sulfated C24 acetylenic fatty acid from marine 
organisms. Fujita et al. 2002 extracted the sodium 1-(12-hydroxy)octadecanyl sulfate from an ascidian 
collected in western Japan, inhibited MMP-2 in 2002. And both natural and synthetic forms inhibited 
MMP-2 with an IC50 value at 9.0 μg/mL; thus the stereochemistry of the hydroxyl group did not 
influence the activity [55]. And after one year, they reported another compound, callysponginol sulfate 
A, a new sulfated C24 acetylenic fatty acid, extracted from the marine sponge, Callyspongia truncate 
[56]. This compound inhibited recombinant MT1-MMP with an IC50 value at 15.0 μg/mL, however the 
desulfated callysponginol sulfate A  did not show any inhibitory activity against MT1-MMP. 
Considering this result as well as the similar activity of structurally unrelated sulfated compounds, the 
MT1-MMP inhibition activity is probably a consequence of the sulfate [56]. 
 
2.4. Other marine natural products MMPIs 
 
Shark cartilage extracts researches are very popular in recently [57]. The compounds extracted from 
shark cartilage (such as NeovastatÒ, AE-941, U-995 etc.) have been investigated on their potential use 
as MMPIs. These compounds were analyzed with regard to their anti-angiogenic and antimetastatic 
effects on the activity of several MMPs [58]，because MMPs are intimately connected with 
angiogenetic and metastatic processes. The results revealed that NeovastatÒ inhibits enzymatic activity 
of MMP-2 with minor inhibition of MMP-1, -7, -9 and -13. And also interestingly the western blot 
analysis evidenced the presence of TIMP-like proteins within AE-941, could be responsible for its 
specific MMP inhibitory property [59]. The tissue inhibitors of metalloprotease 1, 2 and 3 (TIMP-1, -2, 
-3) and tumor suppressor protein genes have been cloned and characterized from shark cartilage 
extracts [52, 60, 61]. 
Alkaloid Ageladine A extract from the marine sponge, Agelas nakamurai ,and Ageladine A inhibited 
not only MMP-2, but also MMPs-1, -8, -9, -12, and -13 with IC50 values of 2.0, 1.2, 0.39, 0.79, 0.33, 
and 0.47 μg/mL, respectively, while its N-methylated derivatives did not inhibit MMP-2. As we know 
that many potent MMP inhibitors are known to bind with Zn
2+ in the catalytic domain. But Ageladine 
A was not capable to chelate Zn
2+. Moreover, the kinetic analysis indicated that inhibition of MMP-2 
by Ageladine A was not competitive when judged in the Lineweaver-Burk plot. Thus, the inhibition 
mechanism of Ageladine A was presumed to be unique [62]. 
The Atlantic cod (Gadus morhua) muscle contains a 21-kDa proteinase inhibitor. The inhibitor had 
properties similar to human TIMP-2. The inhibitor was found to inhibit the gelatin-degrading enzymes 
present in the gelatin-bound fraction. In addition, it inhibited gelatinolytic activity obtained from a 
human macrophage cell medium rich in MMP-9 [63]. 
(+)-Aeroplysinin-1, an antibacterial brominated compound produced by certain sponges, was 
selected during a blind high-throughput screening as new potential antiangiogenic compounds 
obtained from marine organisms. The concentration of MMP-2 in the medium conditioned by 
aeroplysinin-treated cells was clearly lower than that in untreated cell medium. The MMP-2 bands in 
aeroplysinin-treated cell conditioned media were 60 + 4% compared to those of untreated cells, 
whereas extracts of treated cells yielded MMP-2 bands that were almost twofold (1.77 + 0.04) those of 
untreated cells. Thus, aeroplysinin-1 seems to affect mainly the release of MMP-2 to the medium [64].   Mar. Drugs 2009, 7                   
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3. Conclusions   
 
The marine environment is characterized by high biodiversity offering vast variety of natural 
products which could be used as potential drugs，particularly in the area of cancer chemotherapy, such 
like the matrix metalloproteinase inhibitors. Therefore continuation of finding new leads in this area of 
extracting bioactivity compounds from marine natural products will make much sense. 
MMPIs design and synthesis has been done for ages and has gone through several development 
stages. Although many of the synthetic inhibitors of MMPs showed good inhibitory activity, however, 
the compounds do not have an ideal MMPs selectivity, combined with others limitations such as the 
low oral bioavailability, unstable metabolism, biological toxicity, and also these inhibitors in clinical 
trials show excessive side effects. Due to these major shortcomings this type of MMPIs failed to be 
used as drugs [3, 5, 65].   
With MMPIs finding of functionality of MMP`s in normal physiology functions, the development 
of MMPIs entered a new period [66, 67]. In recent years, the non-metal chelating agent class of 
MMPIs reports has begun to appear. Isolating MMPs from marine natural products has been gradually 
gained more attention. Some marine natural products have been isolated with MMPs inhibitory 
activities and further, some compounds have special restraint or high selectivity [68]. Such as 
Ageladine A which inhibit MMP-2 was not competitive judging from the Lineweaver-Burk plot. Thus, 
the inhibition mechanism of Ageladine A was presumed to be unique [62] .These MMPIs will be the 
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